Viewing nowDongkwang Pregabalin Capsule 75 mg
Pregabalin 75mg
Hard capsule · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 201112307 · Notified 2011.12.29 · Insurance code 645905350
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
This medication effectively treats peripheral and central neuropathic pain in adults and is used as an adjunctive therapy for partial seizures in patients with epilepsy. It also helps alleviate the symptoms of fibromyalgia. In other words, it is useful for both pain relief and seizure suppression and is used in the treatment of neurologic disorders.
Administer the total daily dose of this drug, as pregabalin, orally in 2 divided doses, with or without food. Since this drug is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Although clinical studies have also been conducted at a dose of 600 mg per day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this drug, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing instructions. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
7. Pediatric and adolescent patients Use is not recommended in children under 12 years of age or adolescents aged 12 ~17 years because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior; therefore, if mood changes or abnormal behaviors occur during use, consult a healthcare professional immediately. Do not take if allergic to any components contained in this medication or if you have specific genetic conditions such as lactose intolerance. Diabetic patients should be cautious as weight gain may require adjustment of blood sugar control medications. If severe allergic reactions such as angioedema occur, discontinue the medication immediately and notify a healthcare professional. Elderly individuals may be at increased risk of falls due to dizziness or drowsiness, so particular caution should be exercised at the beginning of treatment. Transient blurred vision or changes in vision may occur; if these symptoms appear, consult a healthcare professional. Stopping this medication suddenly may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so doses should be adjusted according to healthcare professionals’ instructions. Due to the risk of drug abuse, patients with a history of mental illness or substance abuse should be particularly cautious when taking this medication. Patients with reduced kidney function may require dosage adjustment and those with heart disease should take it with caution. When taken together with opioid analgesics, the central nervous system depressant effects may be increased, so follow healthcare professional's instructions. This medication may cause dizziness and drowsiness, so changes in symptoms should be assessed before driving or operating machinery. Pregnant women or those planning to become pregnant should consult a healthcare professional before use, as it may affect the fetus in early pregnancy. Breastfeeding mothers should consult a healthcare professional regarding the use and breastfeeding, as this medication may be passed into breast milk. In cases of overdose, severe symptoms such as confusion, drowsiness, and seizures may occur, requiring immediate medical attention. This medication should be kept out of reach of children, and it is safer not to transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain the storage temperature between 15°C and 30°C.
This medication is a capsule with a reddish-brown upper part and a white lower part containing a white or light yellow powder.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.